Le Lézard
Classified in: Science and technology, Business
Subjects: ERN, CCA, ERP

Enghouse Q3 2022 Earnings Release and Conference Call


MARKHAM, ON, Sept. 1, 2022 /CNW/ - Enghouse Systems Limited (TSX: ENGH) announced today it intends to release its third quarter fiscal 2022 results after market close on Thursday, September 8, 2022.

A conference call to discuss the results will be held Friday, September 9, 2022 at 8:45 am ET.

The conference call can be accessed by dialing the following numbers:

Local/ International:

1-416-764-8646       

North American Toll- Free:

1-888-396-8049



Confirmation Code:

56625798

 

This call will also be webcast and can be accessed at the following location:

https://app.webinar.net/KRYPdX4d17J

The call will be archived for one week and will be available at this same web location following the call or by visiting the Enghouse website at www.enghouse.com.

SOURCE Enghouse Systems Limited


These press releases may also interest you

at 16:10
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences: SVB Securities Global Biopharma Conference on Tuesday, February 14 at 11:20 AM Eastern Time Cowen Annual Health Care Conference on...

at 16:10
Horizon Therapeutics plc : RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part...

at 16:05
SPOTLITE360 IOT SOLUTIONS, INC. ("SpotLite360" or the "Company") announces that it has issued $70,000 worth of common shares ("Shares") in the capital of the Company in full satisfaction of a debt related to a marketing agreement (the "Debt...

at 16:05
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") announces that it has received a notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC ("NASDAQ") dated January 26, 2023, notifying the Company that due to...

at 16:05
Versus Systems Inc. ("Versus" or the "Company") today announced that the Company received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") on January 23, 2023 that the Company is not in compliance with the...

at 16:05
Inhibikase Therapeutics, Inc. ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases...



News published on 1 september 2022 at 16:00 and distributed by: